10-Q: America Great Health Reports Increased Sales but Continues to Face Going Concern Challenges in Q3 2024

America Great Health saw a significant increase in sales during the third quarter of 2024, but ongoing losses and a substantial shareholders' deficit raise concerns about the company's ability to continue as a going concern.

Summary

• America Great Health reported a net loss of $228,507 for the three months ended March 31, 2024, and a net loss of $634,833 for the nine months ended March 31, 2024.
• Sales increased to $94,032 for the quarter and $199,019 for the nine-month period, primarily due to new product launches.
• The company's cost of goods sold decreased for the nine-month period, attributed to a shift from higher-cost OEM and stem cell injection businesses to lower-cost protein peptide products.
• Operating expenses increased due to higher stock compensation, original issue discount, and interest expenses.
• The company's cash balance was $51,739 as of March 31, 2024, with a shareholders' deficit of $4,873,784.
• The company's ability to continue as a going concern is dependent on securing additional capital and achieving profitable operations.

Sentiment

Score: 3

Explanation: The document shows some positive signs in sales growth, but the significant net losses, going concern warning, and internal control issues create a negative overall sentiment. The company is in a precarious financial position.

Positives

• The company experienced a substantial increase in sales, indicating market acceptance of new products.
• The shift to lower-cost protein peptide products has improved gross profit margins.
• The company's cash used in operating activities decreased by $96,756 compared to the same period last year.

Negatives

• The company continues to incur significant net losses, raising concerns about its financial sustainability.
• Operating expenses have increased, offsetting some of the gains from increased sales.
• The company has a substantial shareholders' deficit and negative working capital.
• The company's auditors have raised concerns about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain and dependent on securing additional capital and achieving profitability.
• The company has a history of recurring net losses and a significant shareholders' deficit.
• The company's internal controls are not effective, which could lead to material misstatements in future financial statements.
• The company is reliant on loans and advances from its majority shareholder to meet its working capital needs.

Future Outlook

The company intends to finance operating costs over the next twelve months with existing cash on hand and advances from the current majority shareholder. The company is also raising additional capital to achieve profitable operations.

Management Comments

• Management believes that the material weaknesses set forth above did not have an effect on our financial results.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

The company operates in the healthcare sector, focusing on innovative technologies, drug research and development, and medical devices. The increase in sales suggests a growing market for their products, but the financial challenges highlight the competitive nature of the industry and the need for strong financial management.

Comparison to Industry Standards

• The company's revenue growth is a positive sign, but its continued losses and negative equity are concerning when compared to established companies in the healthcare and biotechnology sectors.
• Many companies in the biotechnology sector experience losses during the research and development phase, but the level of debt and the going concern warning are significant red flags.
• Compared to companies like Amgen or Gilead Sciences, which have established revenue streams and positive earnings, America Great Health is in a much earlier and riskier stage of development.
• The company's reliance on related party loans is also a deviation from industry norms, where companies typically seek funding from institutional investors or through public offerings.

Corporate Governance

Related Party Transactions

• The company's current majority shareholder advanced $383,089 to the company as working capital and the company repaid $176,303 to the shareholder during the nine months ended March 31, 2024.
• As of March 31, 2024, the company owed its current majority shareholder $631,928.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be concerned about the company's ability to continue operations.
• Customers may be hesitant to rely on the company due to its financial challenges.
• Suppliers and creditors face increased risk of non-payment.

Next Steps

• The company needs to secure additional capital to continue operations.
• The company needs to improve its internal controls over financial reporting.
• The company needs to achieve profitable operations to ensure its long-term viability.

Key Dates

Keywords

healthcare, biotechnology, pharmaceuticals, financial results, going concern, net loss, sales growth, operating expenses, shareholders deficit, capital raise